Share This Article:

Phase II Study of Irinotecan plus S-1 in Treatment of Advanced Gastric Cancer

Abstract Full-Text HTML XML Download Download as PDF (Size:199KB) PP. 578-583
DOI: 10.4236/jct.2013.42074    3,777 Downloads   5,395 Views   Citations


Objective: The efficacy and safety of irinotecan hydrochloride (CPT-11) plus oral fluoropyrimidine S-1 combination therapy in patients with previously untreated advanced gastric cancer was evaluated. Methods: The regimen comprised CPT-11 plus S-1: CPT-11, 60 mg/m2 (days 1, 15); S-1, 40 - 60 mg/body twice daily (days 1 - 21) followed by a 1-week rest, every 4 weeks. Primary endpoint was response rate. Secondary endpoints were tumor control rate, adverse events, relative dose intensity, and overall survival. Results: Twenty-five patients were enrolled; median age was 66 years. Response rate was 40% (95% confidence interval, 21.1% - 61.3%; complete response in 1; partial response in 9). Tumor control rate was 56.0%, median survival time was 436 days and relative dose intensities were 0.83 for CPT-11 and 0.85 for S-1. Incidence of grade 3 or greater neutropenia, anemia and diarrhea was 16%, 12%, and 12%, respectively.Conclusion: The present results indicate that CPT-11 plus S-1 offers lower treatment-related toxicity than regimens including cisplatin and is effective in patients with advanced gastric cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

H. Bou, A. Tokunaga, H. Suzuki, N. Murata, Y. Sugiyama, N. Fukuda, M. Ishimaru and H. Suzuki, "Phase II Study of Irinotecan plus S-1 in Treatment of Advanced Gastric Cancer," Journal of Cancer Therapy, Vol. 4 No. 2, 2013, pp. 578-583. doi: 10.4236/jct.2013.42074.


[1] A. M. Murad, F. F. Santiago, A. Petroianu, et al., “Modified Therapy with 5-Fluorouracil, Doxorubicin, and Methotrexate in Advanced Gastric Cancer,” Cancer, Vol. 71, No. 1, 1993, pp. 37-41. doi:10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
[2] B. Glimelius, K. Hoffman, U. Haglund, O. Nyren and P. O. Sjoden, “Initial or Delayed Chemotherapy with Best Supportive Care in Advanced Gastric Cancer,” Annals of Oncology, Vol. 5, No. 2, 1994, pp. 189-190.
[3] S. Pyrhonen, T. Kuitunen, P. Nyandoto and M. Kouri, “Randomized Comparison of Fluorouracil, Epidoxorubicin and Methotrexate (FEMTX) plus Supportive Care with Supportive Care Alone in Patients with Non-Resectable Gastric Cancer,” British Journal of Cancer, Vol. 71, No. 3, 1995, pp. 587-591. doi:10.1038/bjc.1995.114
[4] A. Ohtsu, Y. Shimada, K. Shirao, et al., “Randomized Phase 3 Trial of Fluorouracil Alone versus Fluorouracil plus Cisplatin versus Uracil and Tegafur plus Mitomycin in Patients with Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205),” Journal of Clinical Oncology, Vol. 21, No. 1, 2003, pp. 54-59. doi:10.1200/JCO.2003.04.130
[5] Y. Kawano, M. Aonuma, Y. Hirota, H. Kuga, K. Sato, et al., “Intracellular Roles of SN-38, a Metabolite of the Camptothecin Derivative CPT-11, in the Antitumor Effect of CPT-11,” Cancer Research, Vol. 51, No. 16, 1991, pp. 4187-4191.
[6] Y. Sakata, I. Nakao, K. Futatsuki, et al., “An Early Phase II Trial of CPT-11 in Patients with Advanced Gastrointestinal Cancer,” Journal of Japan Society for Cancer Therapy, Vol. 27, No. 12, 1992, pp. 2028-2035.
[7] K. Futatsuki, A. Wakui, I. Nakao, et al., “Late Phase II Study of Irinotecan Hydrochloride (CPT-11) in Advanced Gastric Cancer. CPT-11 Gastrointestinal Cancer Study Group,” Japanese Journal of Cancer and Chemotherapy, Vol. 21, No. 7, 1994, pp. 1033-1038.
[8] K. Shirao, Y. Shimada, H. Kondo, et al., “Phase I-II Study of Irinotecan Hydrochloride Combined with Cisplatin in Patients with Advanced Gastric Cancer,” Journal of Clinical Oncology, Vol. 15, No. 3, 1997, pp. 921-927
[9] N. Boku, A. Ohtsu, Y. Shimada, et al., “Phase II Study of a Combination of Irinotecan and Cisplatin against Metastatic Gastric Cancer,” Journal of Clinical Oncology, Vol. 17, No. 1, 1999, pp. 319-323.
[10] M. Yoshida, N. Boku, A. Ohtsu, et al., “Combination Chemotherapy of Irinotecan plus Cisplatin for Advanced Gastric Cancer: Efficacy and Feasibility in Clinical Practice,” Gastric Cancer, Vol. 4, No. 3, 2001, pp. 144-149. doi:10.1007/PL00011737
[11] T. Yano and A. Ohtsu, “Evaluation of Newly Developed Agents for Gastric Cancer,” Japanese Journal of Cancer Clinics, Vol. 49, No. 7, 2003, pp. 583-588.
[12] T. Fukushima, H. Satake, J. Uchida, et al., “Preclinical Antitumor Efficacy of S-1: A New Oral Formulation of 5-Fluorouracil on Human Tumor Xenografts,” International Journal of Oncology, Vol. 13, No. 4, 1998, pp. 693-698.
[13] T. Shirasaka, K. Nakano, T. Takechi, et al., “Antitumor Activity of 1 M Tegafur-0.4 M 5-Chloro-2,4-Dihydroxypyridine-1 M Potassium Oxonate (S-1) against Human Colon Carcinoma Orthotopically Implanted into Nude Rats,” Cancer Research, Vol. 56, No. 11, 1996, pp. 2602-2606.
[14] K. Sugimachi, Y. Maehara, N. Horikoshi, et al., “An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal Cancers, the S-1 Gastrointestinal Cancer Study Group,” Oncology, Vol. 57, No. 3, 1999, pp. 202-210. doi:10.1159/ 000012032
[15] Y. Sakata, A. Ohtsu, N. Horikoshi, et al., “Late Phase 2 Study of Novel Oral Fluoropyrimidine Anticancer Drug S-1 in Advanced Gastric Cancer Patients,” European Journal of Cancer, Vol. 34, No. 11, 1998, pp. 1715-1720. doi:10.1016/S0959-8049(98)00211-1
[16] H. J. Lenz, C. G. Leichman, K. D. Danenberg, et al., “Thymidylate Synthase mRNA Level in Adenocarcinoma of the Stomach: A Predictor for Primary Tumor Response and Overall Survival,” Journal of Clinical Oncology, Vol. 14, No. 1, 1996, pp. 176-182.
[17] W. Ichikawa, T. Takahashi, K. Suto, et al., “Thymidylate Synthase Predictive Power Is Overcome by Irinotecan Combination Therapy with S-1 for Gastric Cancer,” British Journal of Cancer, Vol. 91, No. 7, 2004, pp. 1245-1250. doi:10.1038/sj.bjc.6602139
[18] H. Takiuchi, H. Nakahara, T. Tsujinaka, et al., “Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (OGSG 0002),” Japanese Journal of Clinical Oncology, Vol. 35, No. 9, 2005, pp. 520-525. doi:10.1093/jjco/hyi148
[19] K. Fujitani, H. Takiuchi, H. Marahara, et al., “A Phase I/II Study of CPT-11 Plus S-1 in Patients with Advanced Gastric Cancer,” Japanese Journal of Cancer Clinics, Vol. 49, No. 7, 2003, pp. 605-609.
[20] Y. Komatsu, H. Takeda. M. Takei, et al., “A Phase I and PK Study of S-1 and Irinotecan (CPT-11) in Patients with Advanced Gastric Cancer (AGC),” Proceedings of the 38th American Society of Clinical Oncology, Orlando, 18-21 May 2002, p. 171.
[21] Y. Yamada, H. Yasui, A. Goto, et al., “Phase I Study of Irinotecan and S-1 Combination Therapy in Patients with Metastatic Gastric Cancer,” International Journal of Clinical Oncology, Vol. 8, No. 6, 2003, pp. 374-380. doi:10.1007/s10147-003-0359-z
[22] Japanese Research Society for Gastric Cancer, “Japanese Classification of Gastric Carcinoma,” Kanehara & Co., Ltd., Tokyo, 1995.
[23] N. Boku, S. Yamamoto, H. Fukuda, et al., “Fluorouracil versus Combination of Irinotecan plus Cisplatin versus S-1 in Metastatic Gastric Cancer: A Randomised Phase 3 Study,” The Lancet Oncology, Vol. 10, No. 11, 2009, pp. 1063-1069. doi:10.1016/S1470-2045(09)70259-1
[24] W. Koizumi, H. Narahara, T. Hara, et al., “S-1 plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (SPIRITS Trial): A Phase III Trial,” The Lancet Oncology, Vol. 9, No. 3, 2008, pp. 215-221. doi:10.1016/S1470-2045(08)70035-4
[25] H. Narahara, H. Iishi, H. Imamura, et al., “Randomized Phase III Study Comparing the Efficacy and Safety of Irinotecan plus S-1 with S-1 Alone as First-Line Treatment for Advanced Gastric Cancer (Study GC0301/TOP-002),” Gastric Cancer, Vol. 14, No. 1, 2011, pp. 72-80. doi:10.1007/s10120-011-0009-5
[26] N. Uedo, H. Narahara, R. Ishihara, et al., “Phase II Study of a Combination of Irinotecan and S-1 in Patients with Advanced Gastric Cancer (OGSG0002),” Oncology, Vol. 73, No. 1-2, 2007, pp. 65-71. doi:10.1159/000120630
[27] T. Katsube, K. Ogawa, W. Ichikawa, et al., “Phase I/II Study of Irinotecan (CPT-11) and S-1 in the Treatment of Advanced Gastric Cancer,” Anticancer Drugs, Vol. 18, No. 5, 2007, pp. 605-610. doi:10.1097/CAD.0b013e3280262460

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.